ETNB 89bio Inc
1,651
$8.63
$0.34
(3.79%)
| Watchers | 1,651 |
| 52-Wk Low | $6.58 |
| 52-Wk High | $22.93 |
| Market Cap | $849.05M |
| Volume | 806,351.00 |
| 52-Wk High | $22.93 |
| 52-Wk Low | $6.58 |
89bio, Inc. (NASDAQ:ETNB) Receives $28.83 Consensus Target Price from AnalystsTicker Report • about 1 month ago
89bio, Inc. (NASDAQ:ETNB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat Ratings reports. Two...
Share to Feed
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the Company or 89bio ) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization...
Related Stocks: ETNB...
89bio, Inc. (NASDAQ:ETNB - Get Free Report)'s share price fell 6.8% during mid-day trading on Monday . The stock traded as low as $10.78 and last traded at $10.85. 182,176 shares traded hands during...
This price move could indicate a change in the trend, and may be a sell signal for investors...
Leerink Partners analyst Thomas Smith has maintained their bullish stance on ETNB stock, giving a Buy rating on March 27. Thomas Smith has given hi...
89bio (NASDAQ:ETNB Get Free Report)s stock had its buy rating reissued by stock analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They...
PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and...
This indicator may be signaling that ETNB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
This indicator may be signaling ETNB's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...